Application for Self-Monitoring of Cardiovascular Risk
Patients who recently suffered a heart attack will use a smart-phone/computer application during cardiac rehabilitation to reduce their risk of a future attack, their re-hospitalizations, their cost of care, and increase their quality of life.
Coronary Artery Disease Which Requires Percutaneous Coronary Intervention(Balloon and/or Stent Treatment).
Device: Self Monitoring Software Application
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Supportive Care
|Official Title:||Application for Self-Monitoring of Cardiovascular Risk|
- Percentage of subjects who completed all tasks in the application. [ Time Frame: Baseline to 3 months ] [ Designated as safety issue: No ]These data will provide the best summary of usabilty of the application.
- User-reported satisfaction with application. [ Time Frame: Baseline to 3 months ] [ Designated as safety issue: No ]These data will provide additional insights into how users view the application interface and help us modify th edesign to enhance compliance.
- Body weight [ Time Frame: Baseline to 3 months ] [ Designated as safety issue: No ]Weight will be the most sensitive indicator that completion of the tasks assigned in the application lead to subsequent behavioral chance and reducton of cardiovascular risk.
|Study Start Date:||May 2013|
|Estimated Study Completion Date:||December 2014|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Self Monitoring of Software Application
log into self monitoring software application from a home computer. Log on 3-4 times weekly for 12 weeks for important reminders, care tips and educational materials.
|Device: Self Monitoring Software Application|
No Intervention: No Intervention
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01883050
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Contact: Pamela R Vega, B.S. 507-255-6884|
|Principal Investigator: Thomas Allison, Ph.D|